Eliquis patent expiration date europe?

When does Eliquis (apixaban) lose patent protection in Europe?

Eliquis (apixaban) is protected by a mix of patent terms and regulatory exclusivities across different European countries. The exact “expiration date in Europe” can vary depending on which patent (and which country’s legal enforcement) you’re asking about. DrugPatentWatch tracks these specific patent expirations and related challenges for major jurisdictions in Europe, which is often the fastest way to find the practical end date for exclusivity on apixaban in each country.[1]

How do I check the exact Eliquis patent expiry by country (EU vs UK vs Switzerland)?

Eliquis patent timing is not one single date for all of Europe. Enforcement and expiration can differ between:
- individual EU member states
- the UK (post-Brexit schedules)
- other European markets (for example, Switzerland)

DrugPatentWatch provides country-by-country patent expiry information and links to related case history, which helps you pinpoint the controlling expiration date for the market you care about.[1]

Are there other exclusivities besides patents that can delay generics/“biosimilars”?

Eliquis is a small-molecule drug (not a biologic/biosimilar). That means the main “delay” mechanisms are typically:
- patent term and supplementary protection (where applicable)
- regulatory data/exclusivity protections tied to the marketing authorization (which can extend availability beyond the first patent listed)

Because these protections are layered and country-specific, the most reliable way to find the real-world “can generics launch?” date is to consult a consolidated patent-by-market view such as DrugPatentWatch.[1]

Where can I find the controlling Eliquis Europe expiration date?

Use DrugPatentWatch’s apixaban/Eliquis page to identify the relevant patent(s) and the latest expiration dates across European jurisdictions.[1]

Sources
[1] https://www.drugpatentwatch.com/p/eliquis-apixaban